GenVec starts Phase II with Biobypass

GenVec (Gaithersburg, Md.) started a double-blind, placebo-controlled Phase II trial of Biobypass, an angiogenic agent, in over 100 patients with moderate to severe intermittent ischemic leg pain who ...